BRILINTA PILLS 90MG

Indications and usage

Brilinta, used simultaneously with Acetylsalicylic acid, is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome:

• Unstable angina.
• Myocardial infarction without ST elevation or myocardial infarction with ST elevation [STEMI]), including patients who have received drug therapy, and patients undergoing percutaneous coronary intervention (CKB) or coronary artery bypass surgery (CABG).

Contraindications

• Hypersensitivity to ticagrelor or any of the components of the drug.
• Active pathological bleeding.
• Intracranial hemorrhage in history.
• Mild or severe liver failure.
• Combined use of ticagrelor with powerful inhibitors of CYP3A4 (for example, Ketoconazole, Clarithromycin, nefazodone, ritonavir and atazanavir).
• Children's age up to 18 years (due to the lack of data on the efficacy and safety of use in this group of patients).

Pregnancy and breastfeeding

Data on the use of the drug Brilinta in pregnant women are missing or limited.In animal studies, ticagrelor caused a slight decrease in maternal body weight gain, a decrease in the vitality of the newborn and its body weight, and growth retardation. Brilinta is not recommended during pregnancy. Available pharmacodynamic, toxicological data in animals showed that ticagrelor and its active metabolites are excreted in milk. The risk for a newborn / infant cannot be excluded. It is not recommended to use Brillinta during breastfeeding.

Dosage and administration

For reception inside. Brilinta drug can be taken regardless of the meal. The use of Brillinta should be started with a single loading dose of 180 mg (two pills of 90 mg) and then continue taking 90 mg twice a day. Patients taking Brillinta should take acetylsalicylic acid daily (from 75 mg to 150 mg with regular use) if there are no specific contraindications. Interruptions in therapy should be avoided. A patient who misses taking Brillinta should take only one 90 mg pill (next dose) at the scheduled time. If necessary, patients taking Clopidogrel, can be transferred to the drug Brillinta. It is recommended to conduct Brillint therapy for 12 months, except in cases of clinical need for early withdrawal of the drug. Data on the use of ticagrelor for more than 12 months is limited.In patients with acute coronary syndrome, early cancellation of any antiplatelet therapy, including Brillinta, may increase the risk of cardiovascular death or myocardial infarction as a result of the underlying disease. It is necessary to avoid premature discontinuation of the drug.

Overdosage

Symptoms: In a single study with an increase in dose, the adverse effect on the gastrointestinal tract was dose-limiting. Other clinically significant adverse events that may have occurred during an overdose were dyspnea and ventricular pauses. In case of overdose, it is recommended to monitor for these undesirable phenomena and monitor the ECG.
Treatment: Brilinta is not displayed during hemodialysis, the antidote is not known. In case of overdose, symptomatic therapy should be carried out in accordance with local standards.In connection with the inhibition of platelets, an increase in the duration of bleeding is the intended pharmacological action of Brillinta overdose, therefore, with the development of bleeding, it is necessary to carry out appropriate supportive measures.

Store at a temperature not higher than 30ºС.